文献速递神经免疫脑血管病

Baló同心圆硬化的临床、影像、病理特征与治疗

Clinical and Radiologic Features, Pathology, and Treatment of Baló Concentric Sclerosis.
PubMed 文献 · Neurology · 2021-05-19

该回顾性研究纳入美国与澳大利亚三级中心的40例Baló同心圆硬化(BCS)患者,38例有MRI资料。研究发现BCS多为单发或并发多活动病灶,部分符合多发性硬化(MS)影像标准,血清AQP4-IgG和MOG-IgG均阴性,病理显示MS特征性改变及少突胶质细胞病变(pattern III),提示BCS可能是MS的独特亚型。

要点

  • BCS可表现为单发(26%)或多发活动性同心圆病灶(45%)。
  • 系列MRI可见病灶径向扩大及环形强化模式动态变化。
  • 所有可检血清AQP4-IgG和MOG-IgG均阴性,病理符合MS pattern III。

核心结论

  • BCS可能是以pattern III免疫病理为特征的多发性硬化独特亚型。

研究设计与样本

  • 回顾性分析美国与澳大利亚三级中心40例BCS病例,其中38例有MRI资料。

主要发现

  • 单发MRI病灶占26%(10/38),45%(17/38)存在>1个活动性同心圆病灶。
  • 索引MRI上33%(13/38)有MS提示性病灶,其中10例满足Barkhof标准。
  • 1个月内系列MRI显示52%(14/27)病灶径向扩大伴T2高信号环数量增加。
  • 初始无强化或中心强化病灶后续出现单/多环强化者占41%(9/22),不完全环强化占14%(3/22)。
  • ADC、DWI与钆增强显示的环状模式不一致见于67%(22/33)。

关键数值与推荐

  • 血清AQP4-IgG(n=26)和MOG-IgG(n=21)在所有可检患者中均阴性。
  • 激素治疗临床应答率为46%(13/28)。
  • 末次随访(中位27.5个月,范围3-100个月)时56%(18/32)呈单相临床病程。
  • 初次发作致死率10%(4/40),症状至死亡中位时间23天(范围19-49天)。
  • 17例病理均显示MS典型表现,活动性脱髓鞘病灶均示少突胶质细胞病变(pattern III)。

临床怎么用

  • 对同心圆样MRI病灶应完善AQP4-IgG和MOG-IgG检测以鉴别其他炎性脱髓鞘病。
  • 系列MRI(含DWI/ADC与增强)有助于观察BCS病灶动态演变。
  • 激素治疗可用于BCS急性期,但需警惕部分患者初次发作致死。

局限性

  • 回顾性设计,样本来自三级中心,可能存在选择偏倚。
  • 部分病例血清或病理资料不完整(如AQP4-IgG仅26例可检)。
  • 随访时间异质(范围3-100个月),长期预后结论受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe clinical, radiologic, and pathologic features of Baló concentric sclerosis (BCS) and assess overlap between BCS and other CNS inflammatory demyelinating diseases. METHODS: Retrospective review of BCS cases from US and Australian tertiary care centers. RESULTS: We identified 40 BCS cases with 38 available MRIs. Solitary MRI lesions were present in 26% (10/38). We saw >1 active concurrent BCS lesion in 45% (17/38). A third (13/38) had multiple sclerosis-suggestive lesions on the index MRI, of which 10 fulfilled Barkhof criteria. In patients with serial MRI performed within 1 month of the index MRI, lesions expanded radially with sequentially increased numbers of T2 hyperintense rings 52% (14/27). Initially nonenhancing or centrally enhancing lesions subsequently developed single or multiple enhancing rings (41%; 9/22) and incomplete enhancing rings (14%; 3/22). Discordance between rings as they appear on apparent diffusion coefficient, diffusion-weighted imaging, and gadolinium-enhanced imaging was observed in 67% (22/33). Aquaporin-4 immunoglobulin G (n = 26) and myelin oligodendrocyte glycoprotein immunoglobulin G (n = 21) were negative in all patients with serum available. Clinical response to steroid treatment was seen in 46% (13/28). A monophasic clinical course was present in 56% (18/32) at last follow-up (median 27.5 months; range 3-100 months). The initial attack was fatal in 10% (4/40). Median time from symptom onset to death was 23 days (range 19-49 days). All 17 patients with pathology available demonstrated typical findings of multiple sclerosis. Patients with active demyelinating lesions all demonstrated oligodendrocytopathy (pattern III). CONCLUSIONS: BCS may be a distinct subtype of multiple sclerosis characterized by pattern III immunopathology.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Jolliffe EA, Guo Y, Hardy TA, et al. Clinical and Radiologic Features, Pathology, and Treatment of Baló Concentric Sclerosis. Neurology. 2021. PMID: 34011576. doi:10.1212/WNL.0000000000012230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。